🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

BRIEF-Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

Published 2017-04-25, 08:08 a/m
© Reuters.  BRIEF-Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis
CTX
-

April 25 (Reuters) - Crescita Therapeutics Inc CTX.TO

* Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

* Crescita Therapeutics - entered development and commercialization license agreement with Taro Pharmaceuticals, unit of Taro Pharmaceutical Industries

* Crescita Therapeutics - under terms of agreement, Crescita has granted Taro exclusive license to rights to sell and distribute Pliaglis in U.S. market

* Crescita Therapeutics Inc - in consideration of rights granted under agreement taro will make an upfront, non-dilutive payment of US$2.0 million to Crescita

* Crescita Therapeutics Inc - under deal Taro will also make up to US$5.75 million in non-dilutive development and sales milestone payments to Crescita

* Crescita Therapeutics Inc - in addition, Crescita and Taro have entered into a fee-for-service development agreement

* Crescita Therapeutics Inc - Crescita retains all rights to Pliaglis in Canada and Mexico

* Crescita Therapeutics Inc - fee-for-service development with Taro wherein co to provide services related to development of Pliaglis and enhanced formulation

* Crescita Therapeutics Inc - co to receive fees related to fee-for service development based on services performed Source text for Eikon: ID:nPn6k6W21a Further company coverage: CTX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.